This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pradofloxacin
DrugBank Accession Number
DB11453
Background

Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 396.422
Monoisotopic: 396.159768715
Chemical Formula
C21H21FN4O3
Synonyms
  • Pradofloxacin

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Aminoquinolines and derivatives / Hydroquinolones / Haloquinolines / Hydroquinolines / Pyrrolopyridines / Pyridinecarboxylic acids / Dialkylarylamines / Piperidines / Aryl fluorides
show 15 more
Substituents
Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Carbonitrile
show 31 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6O0T5E048I
CAS number
195532-12-8
InChI Key
LZLXHGFNOWILIY-APPDUMDISA-N
InChI
InChI=1S/C21H21FN4O3/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29)/t11-,17+/m0/s1
IUPAC Name
7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O

References

General References
  1. Silley P, Stephan B, Greife HA, Pridmore A: Bactericidal properties of pradofloxacin against veterinary pathogens. Vet Microbiol. 2012 May 25;157(1-2):106-11. doi: 10.1016/j.vetmic.2011.11.027. Epub 2011 Dec 2. [Article]
  2. Stephan B, Greife HA, Pridmore A, Silley P: Mutant prevention concentration of pradofloxacin against Porphyromonas gingivalis. Vet Microbiol. 2007 Mar 31;121(1-2):194-5. Epub 2007 Jan 13. [Article]
  3. Spindel ME, Veir JK, Radecki SV, Lappin MR: Evaluation of pradofloxacin for the treatment of feline rhinitis. J Feline Med Surg. 2008 Oct;10(5):472-9. doi: 10.1016/j.jfms.2008.04.003. Epub 2008 Jul 10. [Article]
  4. Mueller RS, Stephan B: Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet Dermatol. 2007 Jun;18(3):144-51. [Article]
  5. Lees P: Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. J Vet Pharmacol Ther. 2013 Jun;36(3):209-21. doi: 10.1111/jvp.12036. Epub 2013 Feb 14. [Article]
  6. Restrepo C, Ihrke PJ, White SD, Spiegel IB, Affolter VK: Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma. J Am Anim Hosp Assoc. 2010 Sep-Oct;46(5):301-11. [Article]
  7. Biswas S, Maggi RG, Papich MG, Breitschwerdt EB: Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin. J Antimicrob Chemother. 2010 Mar;65(3):581-2. doi: 10.1093/jac/dkp459. Epub 2009 Dec 18. [Article]
  8. Govendir M, Norris JM, Hansen T, Wigney DI, Muscatello G, Trott DJ, Malik R: Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Vet Microbiol. 2011 Dec 15;153(3-4):240-5. doi: 10.1016/j.vetmic.2011.06.001. Epub 2011 Jun 15. [Article]
  9. Dowers KL, Tasker S, Radecki SV, Lappin MR: Use of pradofloxacin to treat experimentally induced Mycoplasma hemofelis infection in cats. Am J Vet Res. 2009 Jan;70(1):105-11. doi: 10.2460/ajvr.70.1.105. [Article]
  10. Liu X, Lazzaroni C, Aly SA, Thungrat K, Boothe DM: In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates. Vet Microbiol. 2014 Dec 5;174(3-4):514-22. doi: 10.1016/j.vetmic.2014.10.011. Epub 2014 Oct 25. [Article]
ChemSpider
7978646
RxNav
1367269
ChEMBL
CHEMBL1256815
ZINC
ZINC000003827732
Wikipedia
Pradofloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0589 mg/mLALOGPS
logP0.01ALOGPS
logP-0.49Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.33Chemaxon
pKa (Strongest Basic)9.49Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area96.67 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity105.48 m3·mol-1Chemaxon
Polarizability39.7 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at February 25, 2016 18:53 / Updated at February 21, 2021 18:53